Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: An Eastern Cooperative Oncology Group trial (PA286)

American Journal of Therapeutics

Volumn 3, Issue 11, 1996, Pages 750-754

  Einzig, Avi I ^a   Neuberg, Donna ^b   Wiernik, Peter H ^c   Grochow, Louise B ^d   Ramirez, Guillermo ^e   O'Dwyer, Peter J ^f   Petrelli, Nicholas J ^g  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e University of Wisconsin Health   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

colon cancer; paclitaxel (Taxol)

Indexed keywords

CYTOTOXIC AGENT; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON ADENOCARCINOMA; DRUG RESPONSE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CARCINOMA;

EID: 0030432043     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199611000-00003     Document Type: Article

References (24)

1. Moertel CG: Chemotherapy of gastrointestinal cancer. N Engl J Med 1978;299:1049-1052.
2. Posey LE, Morgan LR: Methyl CCNU versus Methyl CCNU and 5-Fluorouracil in Carcinoma of the Large Bowel. Cancer Treat Rep 1977;61:1453-1458.
3. Baker LH, Talley RW, Matter R, et al.: Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU versus methyl CCNU plus bolus weekly 5-FU: A Southwest Oncology Group Study. Cancer 1976;38:1-7.
4. Falkson E, Falkson HC: Fluorouracil, Methyl CCNU and Vincristine in cancer of the colon. Cancer 1976;38:1468-1470.
5. Engstrom P, Macintyre J, Douglass H Jr, et al.: Combination chemotherapy of advanced bowel cancer. Proc AACR/ASCO 1978;19:384.
6. Lokich JJ, Skarin AT, Mayer RJ, et al.: Lack of effectiveness of combined 5-fluorouracil and Methyl-CCNU therapy in advanced colorectal cancer. Cancer 1977;40:2792-2796.
7. Kemeny N, Yagoda A, Golbey R: Randomized study of two different schedules of Methyl-CCNU, 5-Fluorouracil and Vincristine for metastatic colorectal adenocarcinoma. Proc ACCR/ASCO 1977;18:279.
8. Leyland-Jones BR, O'Dwyer PJ: Biochemical modulation: Application of laboratory models to the clinic. Cancer Treat Rep 1986;70:219-229.
9. Erlichman C, Fine S, Wong A, et al.: A randomized trial of 5-Fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988;6469-6475.
10. Buroker TR, O'Connell MJ, Wieand HS, et al.: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14-28.
11. Arbuck SG: Overview of clinical trials using 5-FU and leucovorin for the treatment of colorectal cancer. Cancer 1988;63:1036-1044.
12. Petrelli N, Herrera L, Rustum Y, et al.: A prospective randomized trial of 5-Fluorouracil versus 5-Fluorouracil and methotrexate in previously untreated patients with advanced colorectal cancer. J Clin Oncol 1987;5:1599-1565.
13. Petrelli N, Douglass HO Jr, Herrera L, et al.: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial, Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7(10):1419-1426.
14. Nobile MT, Rosso R, Sertoli MR, et al.: Randomized comparison of weekly bolus 5-Fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur J Cancer 1992;28A(11):1823-1827.
15. Valone FH, Friedman MA, Wittlinger PS, et al.: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 1989;7(10):1427-1436.
16. Doroshow JH, Multhauf P, Leong L, et al.: Prospective randomized comparison of fluorourcil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990;8(3):491-501.
17. Piedbois P, Buyse M: What can we learn from a metaanalysis of trials testing the modulation of 5-FU by leucovorin? Advanced Colorectal Meta-analysis Project. Ann Oncol 1993;4(2):S1519.
18. Wadler S, Wiernik PH: Clinical update on the role of fluorouracil and recombinant interferon Alfa-20a in the treatment of colorectal carcinoma. Semin Oncol 1990;(1): 16-21.
19. Wadler S, Lembersky B, Atkins M, et al.: Phase II Trial of Fluorouracil and Recombinant Interferon Alfa-2a in Patients with Advanced Colorectal Carcinoma: An Eastern Cooperative Oncology Group Study. J Clin Oncol 1991;9: 1806-1810.
20. McGuire WP, Rowinsky EK (eds.): Paclitaxel in Cancer Treatment, Marcel Dekker, New York, 1995, pp. 1-337.
21. Wiernik PH, Schwartz EL, Straumann JJ, et al.: Phase I Clinical and Pharmacokinetic study of Taxol. Cancer Res 1987;47:2486-2493.
22. Weiss R, Donehower RC, Wiernik PH, et al.: Hypersensitivity reactions from Taxol. J Clin Oncol 1990;8:1263-1268.
23. Oken MM, Creech RH, Tormey DC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
24. Rowinsky EK, McGuire WP, Guarnier T, et al.: Cardiac disturbances during the administration of Taxol. J Clin Oncol 1991;9:1709-1712.